Sarclisa, multiple myeloma and European Medicines Agency

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...
GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
The increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...